Published on 22 September 2020
Latest features in GaBI Journal, 2020, Issue 3
Author(s): Professor Philip D Walson, MD
DOI: 10.5639/gabij.2020.0903.016
2.405 views
Published on 22 September 2020
Author(s): Professor Philip D Walson, MD
DOI: 10.5639/gabij.2020.0903.016
2.405 views
Published on 03 August 2020
ABP 215, administration, bevacizumab, biosimilar, infusion, stability
DOI: 10.5639/gabij.2020.0904.026
16.313 views
Published on 03 August 2020
Author(s): Arianna Bertolani, PhD, Claudio Jommi, MS
biosimilars, Italian national health service, local policies
DOI: 10.5639/gabij.2020.0904.027
10.818 views
Published on 03 August 2020
adalimumab, anti-TNF therapy, biosimilars, clinical trials, injection-site pain, rheumatoid arthritis
DOI: 10.5639/gabij.2020.0903.019
10.458 views
Published on 09 July 2020
2.071 views
Published on 07 July 2020
Author(s): Madelaine A Feldman, MD, FACR, Michael S Reilly, Esq
biological medicines, biosimilar, EU, prescribers, substitution, survey
DOI: 10.5639/gabij.2020.0903.020
7.227 views
Published on 07 July 2020
etanercept, injection pen, needle fear, rheumatoid arthritis, usability, YLB113
DOI: 10.5639/gabij.2020.0903.018
24.099 views
Published on 07 July 2020
Author(s): Elwyn Griffiths, DSc, PhD
ASEAN, biologicals, biosimilars, GMP, regulatory harmonization
DOI: 10.5639/gabij.2020.0903.017
6.450 views
Published on 02 July 2020
Author(s): Professor Philip D Walson, MD
DOI: 10.5639/gabij.2020.0902.008
2.260 views
Published on 26 May 2020
Author(s): GaBI Journal Editor
biosimilar, EMA, regulation, US Food and Drug Administration (FDA)
DOI: 10.5639/gabij.2020.0902.015
7.308 views
Published on 26 May 2020
Author(s): Dirk Lehnick, PhD, Hendrik Wessels, PhD, Josef Höfler, PhD, Karsten Roth, PhD, Ulrike Scholz, PhD
biosimilar, filgrastim, Neulasta®, pegfilgrastim, Pelmeg®, targeted development
DOI: 10.5639/gabij.2020.0903.021
18.505 views
Published on 26 May 2020
Author(s): Adjunct Associate Professor Sia Chong Hock, BSc (Pharm), MSc, Associate Professor Chan Lai Wah, BSc (Pharm) (Hon), PhD, Sia Ming Kian, BSc (Pharm) (Hons)
ASEAN, biopharmaceutical manufacturing, biopharmaceuticals, good manufacturing practice, harmonization, regulatory guidelines
DOI: 10.5639/gabij.2020.0902.010
20.212 views